Lipid abnormality correction by integrase inhibitor among children taking ARt

Abstract

Goal. To estimate a possibility of correction laboratory abnormalities (increased level of cholesterol and/or triglycerides at blood of HIV-positive children) by switch the boosted PI on HIV integrase inhibitor (Raltegravir).
Methods. The retrospective study was conducted in group of 58 HIV-positive children (less 18 yo). Inclusion criteria were increasing level of cholesterol in blood (more than 5,0 mmol/l) and/or the triglyceride (more than 2,3 mmol/l) ART with boosted PI. The ART regime was changed for all children (n=58). Boosted PI was replaced to integrase inhibitor (RAL). RAL formulation (chewable tablets, 25mg and 100mg) used accordingly weight. Time horizon of observation and laboratory control after boosted PI switch was 24 months.
Results. Lab abnormalities in study group (n=58) after switch to RAL were changed: reliable decrease in level of cholesterol (p <0,01), triglycerides (p <0,001), viral load (p <0,001) and growth CD4 count (p <0,05).
Conclusion. Boosted PI switch to integrase inhibitor is providing long-term and effective HIV management and improvement of lipid abnormalities among children.